Consolidated Statements of Cash Flows (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010		Dec. 31, 2009
Operating Activities
Net Income	$ 2,784	$ 2,321		$ 676
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	2,883	2,962		2,827
Purchased in-process research and development charge	0	0		7	[1]
Provision (Credit) for deferred income tax	1	328		(652)
Earnings of nonconsolidated affiliates less than (in excess of) dividends received	(207)	(444)		60
Pension contributions	(806)	(708)		(355)
Net gain on sales of investments	(39)	0		0
Net gain on sales of property, businesses and consolidated companies	(25)	(95)		(256)
Other net (gain) loss	10	(12)		(31)
Net gain on sales of ownership interest in nonconsolidated affiliates	(61)	(25)		(795)
Goodwill impairment loss	0	0		7	[2]
Restructuring charges	0	26		684
Loss on early extinguishment of debt	482	46		56
Asbestos-related credits	0	(54)	[3]	0
Excess tax benefits from share-based payment arrangements	(23)	(20)		(10)
Changes in assets and liabilities, net of effects of acquired and divested companies:
Accounts and notes receivable	(2,184)	(1,209)		(990)
Proceeds from interests in trade accounts receivable conduits	1,737	1,038		0
Inventories	(702)	(750)		63
Accounts payable	376	495		304
Other assets and liabilities	(347)	203		480
Cash provided by operating activities	3,879	4,102		2,075
Investing Activities
Capital expenditures	(2,687)	(2,130)		(1,683)
Construction of assets pending sale / leaseback	(113)	0		0
Proceeds from sale / leaseback of assets	119	0		0
Proceeds from sales of property and businesses	670	1,877		294
Acquisitions of businesses	(8)	(8)		(35)
Purchases of previously leased assets	(30)	(45)		(713)
Investments in consolidated companies, net of cash acquired	(218)	(215)		(15,045)
Proceeds from sales of consolidated companies	56	74		1,563
Investments in and loans to nonconsolidated affiliates	(248)	(107)		(122)
Distributions and loan repayments from nonconsolidated affiliates	295	29		9
Proceeds from sale of ownership interests in nonconsolidated affiliates	93	113		1,413
Purchase of unallocated Rohm and Haas ESOP shares	0	0		(552)
Change in restricted cash	0	436		0
Purchases of investments	(797)	(946)		(580)
Proceeds from sales and maturities of investments	874	1,057		684
Cash provided by (used in) investing activities	(1,994)	135		(14,767)
Financing Activities
Changes in short-term notes payable	(844)	(700)		(418)
Proceeds from notes payable	0	84		0
Payments on notes payable	0	(668)		0
Proceeds from revolving credit facility	0	0		3,000
Payments on revolving credit facility	0	0		(3,000)
Proceeds from Term Loan	0	0		9,226
Payments on Term Loan	0	0		(9,226)
Proceeds from issuance of long-term debt	3,624	3,131		8,283
Payments on long-term debt	(5,337)	(1,387)		(1,790)
Redemption of preferred securities of subsidiaries and payment of accrued dividends	0	0		(520)
Purchases of treasury stock	(19)	(14)		(5)
Proceeds from issuance of common stock	236	181		966
Proceeds from issuance of preferred stock	0	0		7,000
Proceeds from sales of common stock	98	109		555
Issuance costs for debt and equity securities	(27)	(12)		(368)
Excess tax benefits from share-based payment arrangements	23	20		10
Distributions to noncontrolling interests	(42)	(8)		(24)
Contribution from noncontrolling interest	184	100		0
Dividends paid to stockholders	(1,258)	(1,014)		(1,030)
Cash provided by (used in) financing activities	(3,362)	(178)		12,659
Effect of Exchange Rate Changes on Cash	(121)	88		79
Cash Assumed in Initial Consolidation of Variable Interest Entities	3	46		0
Summary
Increase (Decrease) in cash and cash equivalents	(1,595)	4,193		46
Cash and cash equivalents at beginning of year	7,039	2,846		2,800
Cash and cash equivalents at end of year	$ 5,444	$ 7,039		$ 2,846

[1] See Note D for information regarding purchased in-process research and development.

[2] See Note I for information regarding the goodwill impairment loss.

[3] See Note N for information regarding the asbestos-related credit.